Covid19
Conditions
Keywords
Ivermectin, Prophylaxis, COVID-19, Epidemiological link
Brief summary
Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis supplying the drug to close contacts of confirmed cases.
Detailed description
This is a randomized, double-blind, and controlled clinical trial that aims to evaluate the use of oral ivermectin in COVID-19 prophylaxis. The study has two arms in a relationship of 2:1: Experimental Group (EG n=500) and Placebo Group (CG n=250). The sample size was calculated by applying a two-proportion comparison test. Type of two-sided test, 95% confidence or safety level (1-α), 95% statistical power, 75% P1 (proportion in the placebo group), 65% P2 (proportion in the new treatment or intervention group), size sample without adjustment (n = 543), 25% expected proportion of losses, n= 724 sample adjusted for losses. The hypothesis of the study is that treatment with ivermectin may decrease the chance of occurrence/progress of clinical manifestations and onset of severe disease. Whereas control of the contagion on the first days of development of the disease, this treatment with ivermectin in suspected cases of COVID-19 (by epidemiological nexus) would contribute to the control of contagion at the first part of the infection, even in the absence of symptoms. Categorical variables will be represented with frequencies and proportions, while continuous quantitative variables will be expressed as mean ± standard deviation (SD) or as median and interquartile range (IQR). The proportions will be compared using Pearson's Chi-square test or Fisher's exact test as appropriate, and continuous quantitative variables with Student's t test. The estimation of the efficacy of intensive treatment with Ivermectin will be calculated using Kaplan-Meier curves and the differences will be analyzed by means of the log-rank test. The risk will be calculated as a ratio of advantages for Intensive treatment with Ivermectin (Odds Ratio, OR) with its 95% confidence intervals (95% CI). A value of p \<0.05 will be considered significant. Analyzes will be performed using Stata 11.2 software.
Interventions
DRUGIvermectin
0,6mg/kg of weight orally on days 1 and 7
OTHERPlacebo
A substance with similar physical characteristics as ivermectin, without the active drug ingredient
Sponsors
Ministry of Public Health, Argentina
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Double-Blind
Intervention model description
Randomized controlled. Experimental and Control Group in relationship of 2:1
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Over 18 years either sex * Women of childbearing age with a negative pregnancy test * In close contact group or epidemiological nexus of a positive COVID-19 case * Able to understand and grant informed consent * Real-time - polymerase chain reaction test with a negative result
Exclusion criteria
* Known hypersensitivity or allergy to any component of the drug under evaluation * Age under 18 years * Use of immunosuppressants (including systemic corticosteroids) in the last 30 days * Pregnant or lactating * Patients with other acute infectious diseases * Patients with autoimmune disease and/or chronic decompensated diseases * Who have received a vaccine for COVID-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another COVID-19 prophylaxis study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects who were diagnosed with COVID-19 in EG and CG (Negative polymerase chain reaction - real-time). | At 2 weeks | Pearson's Chi-square and proportion test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prophylactic effect associated with patient's preexisting comorbidity | Up to 2 weeks | Logistic regression test |
| Contagion risk. | Up to 2 weeks | Odd Ratio |
Countries
Argentina
Outcome results
None listed